| Literature DB >> 23303127 |
I Wu1, S C Shin, Y Cao, I K Bender, N Jafari, G Feng, S Lin, J A Cidlowski, R P Schleimer, N Z Lu.
Abstract
Induction of T-cell apoptosis contributes to the anti-inflammatory and antineoplastic benefits of glucocorticoids. The glucocorticoid receptor (GR) translational isoforms have distinct proapoptotic activities in osteosarcoma cells. Here we determined whether GR isoforms selectively induce apoptosis in Jurkat T lymphoblastic leukemia cells. Jurkat cells stably expressing individual GR isoforms were generated and treated with vehicle or dexamethasone (DEX). DEX induced apoptosis in cells expressing the GR-A, -B, or -C, but not the GR-D, isoform. cDNA microarray analyses of cells sensitive (GR-C3) and insensitive (GR-D3) to DEX revealed glucocorticoid-induced proapoptotic transcriptomes. Genes that were regulated by the proapoptotic GR-C3, but not by the GR-D3, isoform likely contributed to glucocorticoid-induced apoptosis. The identified genes include those that are directly involved in apoptosis and those that facilitate cell killing. Chromatin immunoprecipitation assays demonstrated that distinct chromatin modification abilities may underlie the distinct functions of GR isoforms. Interestingly, all GR isoforms, including the GR-D3 isoform, suppressed mitogen-stimulated cytokines. Furthermore, the GR-C isoforms were selectively upregulated in mitogen-activated primary T cells and DEX treatment induced GR-C target genes in activated T cells. Cell-specific expressions and functions of GR isoforms may help to explain the tissue- and individual-selective actions of glucocorticoids and may provide a basis for developing improved glucocorticoids.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23303127 PMCID: PMC3563981 DOI: 10.1038/cddis.2012.193
Source DB: PubMed Journal: Cell Death Dis Impact factor: 8.469
Figure 1GR isoforms mediate Jurkat cell apoptosis selectively. (a) Individual GR isoforms were expressed stably in Jurkat cells. Expression level of GR isoforms in each clone is similar as indicated by western blot analysis. Vehicle- or DEX- (100 nM, 48 h) treated cells were examined on parameters including PI staining (b), Annexin-V staining (c), DNA degradation (d), and the level of cleaved PARP (e). Averages (±S.E.M.) of at least three experiments are shown in the bar graphs. *Significantly greater than GRα; **significantly less than GRα, P<0.05, ANOVA followed by Tukey's post hoc test
Figure 2MYC was suppressed by selective GR isoforms. (a) Vehicle- or DEX- (100 nM, 24 h) treated cells showed reduction of MYC protein levels. RPLP was used as a loading control. The average (±S.E.M.) of three experiments are shown in the bar graph. *Significantly less than CON, P<0.05, Student's t-test. (b) Time course of DEX regulation of MYC protein levels in GR-A- or -C3-expressing cells. MYC levels in GR-D3-expressing cells are shown as a control. (c) The role of MYC in DEX sensitivity. Ectopic expression of MYC increased the level of MYC in GR-C-expressing cells and MYCsi knocked down the expression level of MYC in GR-D-expressing cells. Ectopic expression of MYC partially protected, whereas knockdown of MYC sensitized the cells to DEX killing. *Significantly different, P<0.05, Student's t-test. (d) Three IR-GREs (positions are relative to transcription start site) in the MYC regulatory region. (e) ChIP assays demonstrated that DEX (100 nM, 6 h) increased binding of all GR isoforms to two of the three MYC IR-GREs (underlined). *Significantly greater than CON, P<0.05, Student's t-test, n=4 (±S.E.M.). (f) However, DEX reduced the amount of histone H4 acetylation and Pol II activation in cells expressing selective GR isoforms. *Significantly less than CON, P<0.05, Student's t-test, n=4 (±S.E.M.)
Figure 3BIM was induced by selective GR isoforms. Vehicle- or DEX- (100 nM, 24 h) treated cells showed induction of three forms of BIM proteins, EL, L, and S. The averages (±S.E.M.) of three experiments are shown in the bar graphs. *Significantly different, P<0.05, ANOVA followed by Tukey's post hoc test
Genes involved in apoptosis (GO: 0043067) and regulated by the GR-C3, but not the GR-D3, isoform
| NS | ||||
| 330 | 3.74 | 1.09 | ||
| 11 040 | 3.11 | 1.35 | ||
| 92 196 | 2.74 | 1.15 | ||
| 3708 | 2.39 | 1.17 | ||
| 9140 | 2.36 | 1.16 | ||
| 27 242 | 2.16 | 1.20 | ||
| 3621 | 2.07 | 1.28 | ||
| 23 513 | 2.01 | 1.30 | ||
| 3001 | 1.94 | 1.16 | ||
| 50 650 | 1.90 | 1.32 | ||
| 6446 | 1.89 | 1.34 | ||
| 11 214 | 1.84 | 1.28 | ||
| 8531 | 1.83 | 1.17 | ||
| 5295 | 1.81 | 1.24 | ||
| 10 018 | 1.78 | 1.41 | ||
| 5590 | 1.74 | 1.02 | ||
| 5921 | 1.72 | 1.45 | ||
| 7852 | 1.69 | 1.33 | ||
| 5728 | 1.65 | −1.11 | ||
| 4908 | 1.57 | 1.38 | ||
| 57 019 | 1.56 | 1.07 | ||
| 10 276 | 1.56 | −1.08 | ||
| 329 | 1.55 | 1.02 | ||
| 55 179 | 1.55 | 1.07 | ||
| 10 370 | 1.51 | 1.28 | ||
| 41 5116 | −1.53 | 1.07 | ||
| 60 675 | −1.53 | −1.24 | ||
| 83 593 | −1.55 | −1.26 | ||
| 79 156 | −1.56 | −1.24 | ||
| 2769 | −1.66 | −1.13 | ||
| 6304 | −1.83 | −1.20 | ||
| 6659 | −1.97 | −1.14 | ||
| 1032 | −1.99 | −1.18 | ||
| 5896 | −2.03 | −1.12 | ||
| 4609 | −3.39 | −1.32 | ||
Abbreviation: NS, not significant.
Figure 4Real-time RT-PCR confirmation of cDNA microarray results. Averages (±S.E.M.) of at least three real-time RT-PCR experiments comparing vehicle (CON) or DEX (100 nM, 6 h) treatments. *Significantly different from CON, P<0.05, Student's t-test
Figure 5Facilitatory role of TUBA3E in apoptosis. (a) Verification of knockdown of TUBA3E (n=2, average±S.E.M.) in GR-C3-expressing cells and overexpression of TUBA3E in GR-D3-expressing cells. DEX, 100 nM, 6 h. *Significantly different, P<0.05, ANOVA followed by Tukey's post hoc test. (b) DEX (100 nM, 48 h) sensitivity of cells with altered TUBA3E levels. Cell death was examined using PI staining (n=4, average±S.E.M.). *Significantly different, P<0.05, ANOVA followed by Tukey's post hoc test. (c) Localization of tubulin (green) and TUBA3E (red) in GR-C-expressing cells treated with vehicle (CON) or DEX (100 nM, 6 h). Nuclei are indicated in blue (DAPI). Scale bar, 20 μm
Genes commonly repressed by the GR-C3 and -D3 isoforms in the presence of PMA and ionomycin
| 4050 | −4.81 | −3.07 | ||
| 3576 | −8.25 | −2.65 | ||
| 677 | −5.11 | −2.57 | ||
| 4319 | −2.58 | −2.41 | ||
| 1026 | −2.79 | −2.36 | ||
| 8740 | −2.21 | −2.18 | ||
| 8743 | −1.63 | −2.18 | ||
| 6004 | −2.03 | −2.15 | ||
| 79 156 | −1.89 | −2.02 | ||
| 1959 | −2.56 | −2.02 | ||
| 50 617 | −1.54 | −1.94 | ||
| 7124 | −1.72 | −1.91 | ||
| 3002 | −5.23 | −1.80 | ||
| 1647 | −1.71 | −1.75 | ||
| 10 135 | −1.90 | −1.74 | ||
| 1437 | −1.61 | −1.73 | ||
| 2669 | −1.90 | −1.71 | ||
| 29 851 | −1.58 | −1.71 | ||
| 4851 | −1.87 | −1.70 | ||
| 3659 | −3.06 | −1.69 | ||
| 22 822 | −4.65 | −1.67 | ||
| 8459 | −2.68 | −1.61 | ||
| 1649 | −2.74 | −1.61 | ||
| 2841 | −1.94 | −1.57 | ||
| 3775 | −1.80 | −1.57 | ||
| 3399 | −2.56 | −1.55 | ||
| 54 739 | −1.53 | −1.55 | ||
| 444 | −1.52 | −1.54 | ||
| 6304 | −1.84 | −1.54 | ||
| 5366 | −2.35 | −1.54 | ||
| 15 3769 | −1.76 | −1.53 | ||
| 2731 | −1.83 | −1.52 | ||
| 490 | −1.64 | −1.51 | ||
| 51 561 | −2.15 | −1.51 | ||
| 3156 | −1.77 | −1.51 | ||
| 8795 | −1.70 | −1.50 | ||
| 326 | −1.56 | −1.50 | ||
| 26 191 | −1.50 | −1.50 | ||
Figure 6Selective expression of GR isoforms in primary T cells. (a) A representative western blot analysis of the GR isoforms in CD3+ T cells treated with ConA (7.5 μg/ml, 0–5 days). Averages (n=3, average±S.E.M.) of the level of GR isoforms are shown in the line graph (*significantly greater than day 0, P<0.05, one-way ANOVA followed by Tukey's post hoc tests, n=3) and the relative proportions of GR isoforms on day 3 are shown in the bar graph (*significantly greater than day 0, P<0.05, Student's t-test, n=3, ±S.E.M.). (b) DEX (100 nM or 1 μM, 48 h) sensitivity of vehicle (CON) or ConA-treated cells as indicated by DAPI staining. *Significantly greater than CON, P<0.05, one-way ANOVA followed by Tukey's post hoc tests, n=3, ±S.E.M. (c) Real-time RT-PCR analysis of TUBA3E and AIM1 mRNA levels in vehicle (CON)- and DEX- (100 nM 6 h) treated control or ConA- (2.5 μg/ml, 3 days) treated cells. *Significantly greater than CON, P<0.05, one-way ANOVA followed by Tukey's post hoc tests, n=3, ±S.E.M.